Bio-Gene Technology Limited (BGT.AX)
- Previous Close
0.0750 - Open
0.0750 - Bid 0.0650 x 43564400
- Ask 0.0830 x 1724600
- Day's Range
0.0750 - 0.0750 - 52 Week Range
0.0380 - 0.1300 - Volume
1,309 - Avg. Volume
101,970 - Market Cap (intraday)
15.102M - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Jul 26, 2024 - Jul 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University to refine the process for oil extraction; and with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for testing of Flavocide in grain storage. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.
www.bio-gene.com.auRelated News
Performance Overview: BGT.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BGT.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BGT.AX
Valuation Measures
Market Cap
15.10M
Enterprise Value
11.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.09
Enterprise Value/Revenue
19.96
Enterprise Value/EBITDA
-4.34
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.65%
Return on Equity (ttm)
-65.75%
Revenue (ttm)
167.99k
Net Income Avi to Common (ttm)
-2.63M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
3.23M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.06M
Company Insights: BGT.AX
BGT.AX does not have Company Insights